Literature DB >> 1067619

Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells.

T E Carey, T Takahashi, L A Resnick, H F Oettgen, L J Old.   

Abstract

We studied how frequently patients with malignant melanoma have specific antibody to cell surface antigens of cultured autologous melanoma cells as demonstrated by mixed hemadsorption assays. Of 35 patients studied over periods ranging from 1 to 36 months with Stage II, III, and IV disease, two showed consistent and high titered reactivity against autologous melanoma cells, two showed less consistent and intermediate reactivity, seven showed sporatic, low titered reactivity, and the remainder were consistently negative. A detailed analysis was carried out with the sera of one patient with sufficiently high titer against autologous melanoma cells. By direct tests and by absorption analysis with a variety of melanoma and nonmelanoma cell lines which included autologous fibroblasts, the antigen could not be demonstrated on any cell type other than the autologous melanoma.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1067619      PMCID: PMC431008          DOI: 10.1073/pnas.73.9.3278

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  19 in total

1.  Detection of antigens in tissue culture with the aid of mixed hemadsorption.

Authors:  A ESPMARK; A FAGRAEUS
Journal:  Acta Pathol Microbiol Scand Suppl       Date:  1962

2.  Progressive loss of H-2 antigens with concomitant increase of cell-surface antigen(s) determined by Moloney leukemia virus in cultured murine lymphomas.

Authors:  M Cikes; S Friberg; G Klein
Journal:  J Natl Cancer Inst       Date:  1973-02       Impact factor: 13.506

3.  Possible immunological factors in human malignant melanoma in Uganda.

Authors:  M G Lewis
Journal:  Lancet       Date:  1967-10-28       Impact factor: 79.321

4.  The specificity of surface membrane immunofluorescence in human malignant melanoma.

Authors:  M G Lewis; T M Phillips
Journal:  Int J Cancer       Date:  1972-07-15       Impact factor: 7.396

5.  Loss and recovery of phenotypic expression of Gross leukaemia virus.

Authors:  H L Ioachim; B Dorsett; M Sabbath; S Keller
Journal:  Nat New Biol       Date:  1972-06-14

6.  The study of normal and malignant cell antigens by mixed agglutination.

Authors:  R S Metzgar; S R Oleinick
Journal:  Cancer Res       Date:  1968-07       Impact factor: 12.701

7.  The G (Gross) leukemia antigen.

Authors:  L J Old; E A Boyse; E Stockert
Journal:  Cancer Res       Date:  1965-07       Impact factor: 12.701

8.  Demonstration of antibodies against human malignant melanoma by immunofluorescence.

Authors:  D L Morton; R A Malmgren; E C Holmes; A S Ketcham
Journal:  Surgery       Date:  1968-07       Impact factor: 3.982

9.  Continuous culture of seven new cell lines (SK-L1 to 7) from patients with acute leukemia.

Authors:  B Clarkson; A Strife; E De Harven
Journal:  Cancer       Date:  1967-06       Impact factor: 6.860

10.  Lymphoid cells mediating tumor-specific cytotoxicity to carcinoma of the urinary bladder. Separation of the effector population using a surface marker.

Authors:  C O'Toole; V Stejskal; P Perlmann; M Karlsson
Journal:  J Exp Med       Date:  1974-03-01       Impact factor: 14.307

View more
  131 in total

1.  Characterization of an immunodominant cancer-specific O-glycopeptide epitope in murine podoplanin (OTS8).

Authors:  Catharina Steentoft; Katrine T Schjoldager; Emiliano Cló; Ulla Mandel; Steven B Levery; Johannes W Pedersen; Knud Jensen; Ola Blixt; Henrik Clausen
Journal:  Glycoconj J       Date:  2010-08-19       Impact factor: 2.916

2.  Contrasting effects of IFNα on MHC class II expression in professional vs. nonprofessional APCs: Role of CIITA type IV promoter.

Authors:  Laura Pisapia; Giovanna Del Pozzo; Pasquale Barba; Alessandra Citro; Paul E Harris; Antonella Maffei
Journal:  Results Immunol       Date:  2012-09-27

3.  The genealogy of SEREX.

Authors:  Michael Pfreundschuh
Journal:  Cancer Immun       Date:  2012-05-01

4.  Autologous typing: a tedious but orthodox approach for defining human tumor antigens with clarity.

Authors:  Hiroshi Shiku; Toshitada Takahashi
Journal:  Cancer Immun       Date:  2012-05-01

5.  AU cell-surface antigen of human malignant melanoma: solubilization and partial characterization.

Authors:  T E Carey; K O Lloyd; T Takahashi; L R Travassos; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1979-06       Impact factor: 11.205

6.  Specificity analysis of blood group Lewis-y (Le(y)) antibodies generatedagainst synthetic and natural Le(y) determinants.

Authors:  K Kitamura; E Stockert; P Garin-Chesa; S Welt; K O Lloyd; K L Armour; T P Wallace; W J Harris; F J Carr; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

7.  Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine.

Authors:  K Kitamura; P O Livingston; S R Fortunato; E Stockert; F Helling; G Ritter; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

8.  Specific DNA sequence amplification in human neuroblastoma cells.

Authors:  K T Montgomery; J L Biedler; B A Spengler; P W Melera
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

9.  Autologous and allogeneic typing of human leukemia cells: definition of surface antigens restricted to lymphocytic leukemia cells.

Authors:  K Naito; H Yamaguchi; K Horibe; H Shiku; T Takahashi; S Suzuki; K Yamada
Journal:  Proc Natl Acad Sci U S A       Date:  1983-04       Impact factor: 11.205

10.  Tumor localization of alpha-aminoisobutyric acid (AIB) in human melanoma heterotransplants.

Authors:  P S Conti; E M Sordillo; P P Sordillo; B Schmall
Journal:  Eur J Nucl Med       Date:  1985
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.